**Original Article** 

# EyeMirDB: a Web-Based Platform of Experimentally Supported Eye Disease-miRNA Information

**Behnaz Haji Molla Hoseyni**<sup>1</sup>, **PhD; Alireza Meshkin**<sup>2,\*</sup>, **PhD; Ehsan Pournoor**<sup>3,\*</sup>, **PhD** 1 Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.

2 Department of Computer Engineering, Damavand Branch, Islamic Azad University, Damavand, Iran.

3 Basir Eye Health Research Center, Iran University of Medical Sciences, Tehran, Iran.

\*Corresponding Authors: Ehsan Pournoor; Alireza Meshkin

E-mail: e.pournoor@ut.ac.ir; alireza.meshkin@iau.ac.ir

# Abstract

**Background:** Studies of microRNA biology have increased in numerous scientific research domains, including eye science. MicroRNAs (miRNAs) are small non-coding RNAs that operate as post-transcriptional regulators of gene expression by destroying or blocking the translation of target messenger RNA. Recent research has revealed the functions of several miRNAs in the regulation of pathological ocular disease, implying that miRNAs could be used as biomarkers and therapeutic targets in eye diseases. Many of the ocular miRNAs' target genes are still unknown. It seems that more research is needed to better understand their role. Despite significant efforts to investigate the miRNA of eye disease, a complete platform of frequent ocular disease with genes, pathways, and miRNA is still unavailable.

**Material and Methods:** Since the most important part of designing a platform is collecting reliable data, three well-known databases were used as the main data source: DisGeNET, OMIM, and KEGG. The curated genes involved in each disease were manually collected. Then, the annotation information like gene's sequence, description, chromosome's number, start and end loci were extracted from the Ensembl data source. Gene's pathway information was earned from KEGG and Reactome. Finally, experimentally validated gene's related miRNA has been collected from miRecords, miRTarBase, and TarBase. In order to consider miRNAs expression in ocular tissues, we reported their expression in terms of RPM (based on miTED).

**Results:** we present EyeMirDB (http://eyemirdb.databanks.behrc.ir/), a web-based platform of consisting of all predicted and validated miRNAs. Information on the annotation of miRNA-related genes was also collected in order to better understand the effects of miRNA. Pathways by which these genes are active were also identified. Right now, EyeMirDB contains 429 curated genes, 1258 pathways, and 2596 validated miRNAs of 25 prevalent ocular diseases.

**Conclusion:** We introduce EyeMirDB, a web-based platform of Eye diseases-related interactions including disease-gene, gene-miRNA, gene-pathway curated information, and annotations, with the optionality of studying all these entities from different viewpoints. This data portal is a good entry point for ocular disease researchers.

Keywords: Web-Based Platform; Eye Disease; Gene; miRNA; Pathway.

Article Notes: Received: Jan. 07, 2020; Received in revised form: Feb. 15, 2020; Accepted: Mar. 16, 2020; Available Online: Jun. 23, 2020.

**How to cite this article:** Haji Molla Hoseyni B, Alireza Meshkin A, Pournoor E. EyeMirDB: a Web-Based Platform of Experimentally Supported Eye Disease-miRNA Information. Journal of Ophthalmic and Optometric Sciences . 2020;4(3): 32-41.

32

## Introduction

The Human Genome Project, which ran from 1990 to 2003, provided complete and exhaustive data on human genome configurations in all their complexities, ushering in the postgenomic era <sup>(1)</sup>. This time is set apart to a limited extent by broad examinations on noncoding RNAs (ncRNAs), which do not encode for proteins yet still record for over 98.5 % of human genome records (1-3). Although many studies on the roles of transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs) have been conducted, non-coding RNAs (ncRNAs) such as long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs) have only recently been discovered to play a role in pathological and physiological processes. Among these regulatory ncRNAs, miRNAs are the most widely studied ncRNAs in biomedical research.

The discovery of microRNAs has been the most exciting new development in RNA biology in the last two decades (miRNAs). MiRNAs are members of the non-coding RNA family, which consists of genomically encoded untranslated RNA molecules ranging in size from 18 to 24 nucleotides. They regulate protein-coding genes by interfering with the mRNAs' original instructions. MiRNA expression is spatially and temporally regulated. This is why they were initially referred to as small temporal RNAs. MiRNAs have been discovered in some viruses as well as all multicellular eukaryotes such as algae, plants, and animals. MiRNAs regulate many important biological processes, including cell growth, cell death, development, and differentiation. According to the findings, miRNAs play an important role in the genome-wide regulation of gene expression and add a layer of complexity to gene expression regulation (2). MiRNA dysregulation has been linked to a variety

of diseases such as cancer, cardiovascular infections, and neurological disorders. MiRNA inherited variants have also been linked to a few acquired disorders, including hearing loss and embryo development. Given their biological significance, miRNAs are currently regarded as astute infection biomarkers and likely restorative focuses for expanding new intercessions <sup>(4-6)</sup>.

The human eye is a complicated organ with multiple separate tissues (e.g., lens, cornea, retina, and iris) that all perform different activities in order to detect a visual image. The lens, for example, is a very simple structure made of columnar and elongated lens epithelial cells that focuses incoming light onto the retina. The retina, on the other hand, is a multilayered tissue that contains a variety of cell types, including photoreceptors, amacrine cells, ganglion cells, and bipolar cells, and analyzes and transmits visual signals to the brain. The role of miRNA in the development and function of the eye is unknown, but it is being investigated. Several studies published in the last five years have improved our understanding of ocular miRNA expression (7). Growing evidence suggests that miRNAs and their biogenesis machinery are altered and dysregulated in neovascular eye diseases such as diabetic retinopathy (DR), age-related macular degeneration (AMD), and retinopathy of prematurity (ROP), suggesting the potential for miRNAs to be used as biomarkers and therapeutic targets (8). Because of their critical roles in normal development and illness, recent research has shown that miRNAs are effective indicators or molecular targets for potential treatments. Following their recent discovery via miRNA expression analysis, researchers are now looking into the role of miRNAs in the eye. Many of the target genes of these ocular miRNAs are still unknown.

Although many efforts have been made to study miRNAs in ophthalmic diseases, there is still no comprehensive database of common ophthalmic diseases involving genes, pathways and miRNAs. Therefore, there is an urgent need for a reliable data source from miRNA data for eye diseases. The aim of this study is presenting EyeMirDB a novel source that, for the first time comprises 429 curated genes, 1258 pathways, and 2596 validated miRNAs associated with 25 common ocular disorders <sup>(9)</sup>.

## Materials and methods

## **Data sources**

EyeMirDB currently holds 429 curated genes, and 2596 validated miRNA of humans, representing a comprehensive coverage of annotation profile for 25 common eye diseases. EyeMirDB data collection pipeline is shown in figure 1.

Since the most important part of designing a platform is collecting reliable data, three wellknown databases were used as the main data source: 1. DisGeNET, a discovery platform that houses one of the most comprehensive publicly available libraries of genes and variations linked to human disorders (10), 2. OMIM, a free authoritative database of human genes and genetic traits that is updated daily <sup>(11)</sup>. 3. KEGG, a database resource for understanding high-level functions and utilities of biological systems, such as the cell, organism, and ecosystem, using molecularlevel data, particularly large-scale molecular datasets generated by genome sequencing and other high-throughput experimental technologies (12-14).

As can be seen in the pipeline (Figure 1), to collect data, disease information was first searched in the KEGG and OMIM,

and DisGeNet databases. The collected information was placed in the disease table. Then, the curated genes involved in each disease were manually collected from the three mentioned databases and placed in the genedisease table. Duplicate genes were removed. In this table, in addition to gene symbol and disease name, three binary values were considered that indicate whether the reported gene was extracted from that source. The annotation information like gene's sequence, description, chromosome's number, start and end loci were extracted from the Ensembl data source (a genome browser for vertebrate genomes that aids comparative genomics, evolutionary biology, sequence variation, and transcriptional regulatory studies (15) ), and Ensemble id, Entrez id, gene name, gene symbol, UniProt Id, OMIM Id obtained from NCBI (16). This step was carried out using the R packages biomaRt (17) and org.Hs.eg.db (18). All this data is available in the gene source.

Gene's pathway information was earned from KEGG and Reactome <sup>(19)</sup>. reactome.db <sup>(20)</sup> And KEGG.db <sup>(21)</sup> R packages were used to manage the pathways. The results are in Gene-Pathway and pathway table. Gene-Pathway entries are pathway names and related genes. For the pathways, their name, id in KEGG or Reactome, were extracted

And finally, experimentally validated gene's related miRNA has been collected from miRecords <sup>(22)</sup>, miRTarBase <sup>(23)</sup>, TarBase <sup>(24)</sup>, and predicted gene's related miRNA was collected from diana\_microt <sup>(25)</sup>, elmmo <sup>(26)</sup>, microcosm <sup>(27)</sup>, Miranda <sup>(28)</sup>, mirdb <sup>(29)</sup>, pictar <sup>(30)</sup>, pita <sup>(31)</sup>, and targetscan <sup>(32)</sup>. The miRNA annotation information such as Accession, gene family, chromosome, hairpin, sequence, mature miRNA id from miRBase <sup>(33)</sup>. For these steps, multiMiR <sup>(34)</sup> and mirbase.db <sup>(35)</sup> R packages were used, respectively. In order to




Figure 1: EyeMirDB data collection pipeline. First, the information of each disease was extracted manually from KEGG, OMIM and DisGeNet database. Then genes associated with each disease were obtained and their annotations were obtained from the Ensembl and NCBI databases using R packages biomaRt and org.Hs.eg.db. In addition, the pathway's data related to each gene were collected from two databases, KEGG and Reactome. In this process, reactome.db and KEGG.db R packages were used. Finally, miRNA data related to each gene were extracted from eleven different sources (diana\_microt, elmmo, microcosm, Miranda, mirdb, pictar, pita, targetscan, miRecords, miRTarBase, TarBase). R Package multiMiR was used for this purpose. miRNA annotation data from miRBase was also collected with the help of the mirbase.db R package

consider miRNAs expression in ocular tissues, we inserted their expression level in terms of RPM based on miTED <sup>(36)</sup> database.

## Results

As we mention before, we focused on 25 prevalent ocular diseases. Diseases are divided into three main categories: Neuropathy (Cataract, retinal neovascularization, corneal neovascularization, neuromyelitis optica, posterior capsule opacification), metabolic disease (diabetic retinopathy, diabetic cataract), Nervous system disease (myopia, primary open-angle glaucoma, glaucoma, Vogt-Koyanagi-Harada disease, keratoconus, retinitis pigmentosa), Cancer (uveal melanoma, retinoblastoma), Vascular disease

(proliferative vitreoretinopathy, Behcet's disease), age-related disease (Exfoliation syndrome, age-related cataract, age-related macular degeneration), systemic autoimmune disorder (primary Sjögren's syndrome), Congenital disorder (pterygium, strabismus, Volkmann cataract) and Infectious disease (herpes simplex virus).

We collect data on 429 curated genes based on these diseases. We also retrieved annotation data for each gene. Approximately 11.6 % of the genes belonged to chromosome 1, 7.4 % to chromosome 6, and 81 % to the rest of the chromosomes. To complete the information, we looked at the pathways for each gene. The total number of detected pathways was

1258. Finally, we got 2596 miRNA, 16687 validated gene-miRNA associations. 164 and 145 of miRNAs are located in chromosome 1 and x respectively and for other chromosome we have less than this number. Result of this miRNA distribution on chromosomes, can show the effect of gender on the disease, this could be a matter for further investigation by researchers. Among validated gene-miRNA associations 11,839 of them are reported in the miRTarBase, 10138 in TarBase and only 183 of them repoted in miRecords. In the expriment column related to the validated gene-microRNA association table, we see 68 techniques, among which Degradome sequencing, PAR-CLIP and HITS-CLIP were the most common. Support type of these interactions belongs to Functional MTI, Functional MTI (Weak), Non-Functional MTI, Non-Functional MTI (Weak), negative and positive, The highest frequency is related to positive and Functional MTI (Weak).

36


#### Web portal

The EyeMirDB is developed by the .NET MVC technology. In the server-side, it is programmed by C#, powered by Razor, and in the client-side, JQuery, HTML5, and bootstrap. Its data technology is MSSQL with the LINQ object relational mappings and EntityFramework. The homepage of EyeMirDB is demonstrated in figure 2.

Using the three boxes of Eye Diseases, Genes, and Search miRNA, it is possible to study ocular diseases from different viewpoints. In the Eye Disease tab (Figure 3); all eye diseases are listed with the capability of detailed investigations.

As mentioned previously, these details contains of disease title, description, links to other sources and its involved genes, which could be viewed in details (shown in figure 4).

Moreover, the search tab includes the options of gene and miRNA research. As demonstrated in figure 5, inside the EyeMirDB, we provided



EveMirDB Eye Diseases Genes Search - Download Resources -

#### List of Eye diseases

In the following table, list of eye disease was provided to be studied in detail

Title	KEGG Id	OMIM Id	
cataract	H01202	-	
diabetic retinopathy	H01457	-	
myopia	H02041	-	
primary open-angle glaucoma	H00612	137760	
uveal melanoma	-	155720	
retinal neovascularization	-	-	
corneal neovascularization	-	-	
retinoblastoma	H01513	180200	
proliferative vitreoretinopathy (PVR)	H01798	193235	
Exfoliation syndrome (XFS)	-	177650	
primary Sjögren's syndrome (pSS)	H01502	270150	

Figure 3: Eye Diseases list. For every record, the details information is provided

the capability of searching a microRNA using its Mature ID, Pre-Mature ID or its sequence. A typical search result is depicted in figure 6.

#### Discussion

Finding disease-related microRNA can help researchers better understand the mechanism

of disease. It can also be effective in prescribing medication. In this platform, in order to help researchers, we tried to introduce diseaserelated microRNA in two groups: validated and predicted. We introduce EyeMirDB, a web-based platform of Eye diseases-related interactions including disease-gene, gene-

EyeMirDB Eye Diseases Genes Search - Download Resources -

#### Details for disease: retinoblastoma

The retinoblastoma is an eye tumor of childhood that arises in the retina and represents the most common intraocular malignancy of infancy and childhood. Tumor formation usually begins with mutation in both alleles of the retinoblastoma tumor suppressor gene RB1, followed by a series of other genetic alterations that correlate with the clinical stage and pathologic findings of the tumor. In retinoblastoma, mutation of RB1 leads to dysfunction or absence of the Rb protein. These mutations promote tumour development by deregulating the E2F family of transcription factors leading to uncontrolled cell cycle progression.

Title	retinoblastoma
KEGG ID	H01513 🔗 (more details)
OMIM ID	180200
DisGeNet ID	C0035335 🔗 (more details)
Involved Genes	TP53 / NF1 / RB1 / MDM4 / MDM2 / KIF14 / CDH11 / KIF1B / SDHB / TMEM127 / DPP10 / VHL / RASSF1 / ACY1 / HDAC2 / LPA / CFTR / FGFR1 / LALL / SYK / RET / SLC22A18 / MEN1 / ANC / SDHD / MAX / APRT / FASN / E2F1 / BCR / CHEK2 / MTM1 / BCOR / CDKN2A /

Back to List

#### Figure 4: Disease Search Result page

Journal of Ophthalmic and Optometric Sciences. Volume 4, Number 3, Summer 2020

37

EyeMirDB Eye Diseases Genes Search - Download Resources -					
Search					<u></u>
To search any miRNA, fill the following boxes.					
Mature ID	hsa-miR-548ar-3p				
Pre-Mature ID					
Sequence					
					$\widehat{\times}$
	Search				
Mature ID	Mature Accession	Pre-Mature ID	Pre-Mature Accession	Family	
hsa-miR-548ar-3p		hsa-mir-548ar	MI0019131	MIPF0000317	Ľ

Figure 5: miRNA search form. In this page, looking for miRNAs are provided through their Mature ID, Pre-Mature ID, and their sequence

miRNA, gene-pathway curated information, and annotations, with the optionality of studying all these entities from different viewpoints. This data portal is a good entry point for ocular disease researchers (37).

# Conclusion

miRNAs operate as post-transcriptional

EyeMirDB Eye Diseases Genes Search - Download Resources -		
Details for miRNA: hsa-miR-548ar-3p		
Mature ID	hsa-miR-548ar-3p	
Mature Accession		
Pre-Mature ID	hsa-mir-548ar	
Pre-Mature Accession	MI0019131 & (more details)	
family	MIPF0000317	
chromosome	13	
Pre-Mature Location	115009980	
Gene Targets	VIM / NR3C1 /	
sequence	UAAAACUGCAGUUAUUUUUGC	

Back to List

## Figure 6: miRNA search result

regulators of gene expression by destroying or blocking the translation of their target mRNAs. Recent studies have revealed the functions of several miRNAs in the regulation of pathological ocular disease, implying that miRNAs could be used as biomarkers and therapeutic targets in eye diseases. Herein, we introduce EyeMirDB, a platform of Eye diseases-related interactions including disease-gene, gene-miRNA, gene-pathway curated information, and annotations, with the optionality of studying all these entities from different viewpoints. This data portal is a good entry point for ocular disease researchers.

# Acknowledgements

Here we commend the efforts of Ms. Fatemeh Vafaee Sharbaf, who helped in the collection of data and writing the article.

# **Authors ORCIDs**

Behnaz Haji Molla Hoseyni:

<sup>D</sup> https://orcid.org/0000-0002-8733-4139

Alireza Meshkin: ORCID:

<sup>10</sup> https://orcid.org/0000-0002-7046-4404

Ehsan Pournoor, ORCID:

<sup>10</sup> https://orcid.org/0000-0001-7609-1816

# References

1. ander ES. Initial sequencing and analysis of the human germane. Nature. 2001;409:860-921.

2. Pasquinelli AE, Hunter S, Bracht J. MicroRNAs: a developing story. Curr Opin Genet Dev. 2005;15(2):200–5.

3. Ahmadi H, Ahmadi A, Azimzadeh-Jamalkandi S, Shoorehdeli MA, Salehzadeh-Yazdi A, Bidkhori G, et al. HomoTarget: a new algorithm for prediction of microRNA targets in Homo sapiens. Genomics. 2013;101(2):94-100.

4. Ghasemi M, Seidkhani H, Tamimi F, Rahgozar M, Masoudi-Nejad A. Centrality measures in biological networks. Current Bioinformatics. 2014;9(4):426-41.

5. Kouhsar M, Azimzadeh Jamalkandi S, Moeini A, Masoudi-Nejad A. Detection of novel biomarkers for early detection of Non-Muscle-Invasive Bladder Cancer using Competing Endogenous RNA network analysis. Scientific reports. 2019;9(1):1-15.

6. Masoudi-Sobhanzadeh Y, Omidi Y,

Amanlou M, Masoudi-Nejad A. Trader as a new optimization algorithm predicts drugtarget interactions efficiently. Scientific reports. 2019;9(1):1-14.

 Huang KM, Dentchev T, Stambolian D. MiRNA expression in the eye. Mamm genome. 2008;19(7):510–6.

8. Liu C-H, Huang S, Britton WR, Chen J. MicroRNAs in vascular eye diseases. Int J Mol Sci. 2020;21(2):649.

9. Masoudi-Sobhanzadeh Y, Omidi Y, Amanlou M, Masoudi-Nejad A. DrugR+: a comprehensive relational database for drug repurposing, combination therapy, and replacement therapy. Computers in biology and medicine. 2019;109:254-62.

10. Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, Ronzano F, Centeno E, Sanz F, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48(D1):D845–55.

11. McKusick V. Online Mendelian Inheritance in Man, OMIM<sup>TM</sup>. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), 2000. World Wide Web URL https//omim org. 2009;

12. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.

13. Masoudi-Nejad A, Goto S, Endo TR, Kanehisa M. KEGG bioinformatics resource for plant genomics research. Plant Bioinformatics: Springer; 2007. p. 437-58.

14. Masoudi-Nejad A, Goto S, Jauregui R, Ito M, Kawashima S, Moriya Y, et al. EGENES: transcriptome-based plant database of genes with metabolic pathway information and expressed sequence tag indices in KEGG. Plant Physiology. 2007;144(2):857-66.

15. Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, Billis K, et al. Ensembl 2018. Nucleic Acids Res. 2018;46:D754–61.

16. Sayers EW, Barrett T, Benson DA, Bolton E, Bryant SH, Canese K, et al. Database resources of the national center for biotechnology information. Nucleic Acids Res. 2012;40(D1):D13–25.

17. Guberman JM, Ai J, Arnaiz O, Baran J, Blake A, Baldock R, et al. BioMart Central Portal: an open database network for the biological community. Database. 2011;2011.

18. Carlson M, Falcon S, Pages H, Li N. org.Hs. eg. db: Genome wide annotation forHuman. R package version. 2019;3(2):3.

19. Griss J, Viteri G, Sidiropoulos K, Nguyen V, Fabregat A, Hermjakob H. ReactomeGSAefficient multi-omics comparative pathway analysis. Mol Cell Proteomics. 2020;19(12):2115–25.

20. Ligtenberg W. reactome. db: A set of annotation maps for reactome. R Packag version 168 0. 2019.

21. Carlson M, Falcon S, Pages H, Li N. KEGG.

db: A set of annotation maps for KEGG. R Packag version. 2016;3(3):10–18129.

22. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009;37(suppl\_1):D105–10.

23. Huang H-Y, Lin Y-C-D, Li J, Huang K-Y, Shrestha S, Hong H-C, et al. miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res. 2020;48(D1):D148–54.

24. Karagkouni D, Paraskevopoulou MD, Chatzopoulos S, Vlachos IS, Tastsoglou S, Kanellos I, et al. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions. Nucleic Acids Res. 2018;46(D1):D239–45.

25. Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, et al. DIANA-microT web server v5. 0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 2013;41(W1):W169–73.

26. Gaidatzis D, van Nimwegen E, Hausser J, Zavolan M. Inference of miRNA targets using evolutionary conservation and pathway analysis. BMC Bioinformatics. 2007;8(1):1–22.

27. Rose D. MicroRNAs in Cancer Translational Research: The Microcosm of Cancer Diagnosis, Prognosis, and Therapy. Front Genet. 2012;3:42.

28. Sonawane AR, Platig J, Fagny M, Chen CY, Paulson JN, Lopes-Ramos CM, et al. Understanding Tissue-Specific Gene Regulation. Cell Rep. 2017 Oct 24;21(4):1077– 88.

29. Riffo-Campos ÁL, Riquelme I, Brebi-Mieville P. Tools for sequence-based miRNA target prediction: what to choose? Int J Mol Sci. 2016;17(12):1987.

30. Krek A. Grü n D, Poy MN, Wolf R,

Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. 2005. Combinatorial microRNA target predictions. Nat Genet. 37:495–500.

31. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet. 2007;39(10):1278–84.

32. McGeary SE, Lin KS, Shi CY, Pham TM, Bisaria N, Kelley GM, et al. The biochemical basis of microRNA targeting efficacy. Science (80-). 2019;366(6472):eaav1741.

33. Griffiths-Jones S, Grocock RJ, Van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34(suppl\_1):D140–4.

34. Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, et al. The multiMiR R package and database: integration of microRNA-target interactions along with their disease and drug associations. Nucleic Acids Res. 2014;42(17):e133-e133.

35. Reid JF. mirbase. db: miRBase: the microRNA database. R Packag version. 2013;1(1).

36. Kavakiotis, Ioannis, Athanasios Alexiou, Spyros Tastsoglou, Ioannis S. Vlachos, and Artemis G. Hatzigeorgiou. "DIANA-miTED: a microRNA tissue expression database." Nucleic Acids Research 50, no. D1 (2022): D1055-D1061.

37. Najafi A, Bidkhori G, H Bozorgmehr J, Koch I, Masoudi-Nejad A. Genome scale modeling in systems biology: algorithms and resources. Current genomics. 2014;15(2):130-59.

### **Footnotes and Financial Disclosures**

#### **Conflict of interest:**

The authors have no conflict of interest with the subject matter of the present manuscript.